ABOUT THE MEETING

The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.

Over the course of five days, participants will receive exclusive access to more than 2,500 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more.

The program is organized into eight distinct theme areas, allowing you to focus on your specialty or expand your knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutic
- Epidemiology/Genetics
- Immunology/Transplantation
- Insulin Action/Molecular Metabolism
- Integrated Physiology/Obesity
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest meeting focused on diabetes—the American Diabetes Association’s 76th Scientific Sessions!

LOCATION AND DATES

The meeting will take place at the Ernest N. Morial Convention Center, 900 Convention Center Boulevard, New Orleans, LA 70130.

The program will begin on Friday, June 10 at 11:45 a.m. with our new Mini-Symposia sessions and conclude on Tuesday, June 14 at 12:15 p.m. after the ADA Presidents Oral Session.

TABLE OF CONTENTS

| Accreditation Statements | Page 7 |
| City Information | Page 4 |
| Day-At-A-Glance Schedule | Pages 8-12 |
| Hotel Information | Page 6 |
| Learning Objectives | Page 2 |
| Meeting Highlights | Pages 3-4 |
| Sessions | Pages 13-25 |
| Registration Information | Pages 5-6 |
| Travel Information | Page 6 |

LEARNING OBJECTIVES

The Scientific Sessions offers comprehensive educational programming covering the latest in the field of diabetes. The program is designed for physicians, scientists, researchers, nurses, dietitians, pharmacists, psychologists, and other health care professionals.

At the conclusion of this activity attendees will be able to:
- Identify the 2016 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes.
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia.
- Apply clinical decision making tools to the assessment and treatment of the complications related to diabetes.
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes.
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes.
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients.
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes.

IMPORTANT DATES TO REMEMBER

| Abstract Submission Deadline | March 14 |
| Late breaking abstracts | March 14 |
| Registration and Housing Deadlines | |
| Last day to register at the Advance rate | April 28 |
| Last day to cancel meeting registration and receive a partial refund (50% of registration fee) | April 28 |
| Last day to reserve hotel rooms | May 13 |
| Last day to register online | June 2 |
| Cancel hotel reservations to avoid penalty | 72 hours prior to arrival |
MEETING HIGHLIGHTS

Special Addresses and Award Lectures
- President, Health Care & Education Address
  Margaret A. Powers, PhD, RD, CDE
- President, Medicine & Science Address
  Desmond Schatz, MD
- Banting Medal for Scientific Achievement
  Barbara B. Kahn, MD
- Outstanding Scientific Achievement Award Lecture
  Tamas L. Horvath, DVM, PhD
- Outstanding Educator in Diabetes Award Lecture
  Sheri R. Colberg-Ochs, PhD
- Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Edward W. Gregg, PhD
- Richard R. Rubin Award Lecture
  Elizabeth A. Walker, PhD, RN
- Roger Pecoraro Award Lecture
  Nicolaas C. Schaper, MD, PhD
- Norbert Freinkel Award Lecture
  H. David McIntyre, MD, FRACP
- Edwin Bierman Award Lecture
  Clay F. Semenkovich, MD

Poster Presentations
Explore over 2,000 original posters displayed in the Poster Hall on Saturday, Sunday, and Monday. Poster presenters will be at their poster boards for two hours on an assigned day to discuss their research.

ADA Presidents Oral Session
Don’t leave the meeting until after you hear the best, cutting-edge research the Scientific Sessions has to offer during the ADA Presidents Oral Session. Featured abstracts will highlight the most recent and innovative advances in both basic and clinical science.

Moderated Poster Discussions (Formerly Guided Audio Poster Tours)
Listen in as moderators share their perspectives and highlight novel or recent advancements in question and answer discussions with poster presenters.

New this year! Due to the overwhelming popularity of the moderated poster discussions, select discussions will be presented in our new e-Poster Theaters. The e-Poster Theaters are designed to accommodate larger crowds, making for a much more comfortable and enjoyable learning experience.

Interactive Online Posters
Unable to meet with a poster presenter? Don’t worry—each poster presented at the Scientific Sessions will have a corresponding QR code on its board. Scan the barcode with your smartphone, tablet, or handheld device to access an electronic version of the poster, corresponding abstract, and audio commentary (if provided). Computer stations will also be located within the Poster Hall for electronic poster viewing.

Scientific Sessions App
Access the meeting on-the-go. Download the Scientific Sessions app to access meeting information on your smartphone, tablet, or handheld device. Features include a customizable calendar and itinerary builder, exhibitor listing with interactive booth map, social media interaction, and special meeting alerts. Visit scientificsessions.diabetes.org in early May for download details.

Exhibit Hall
The Exhibit Hall is a vital part of the Scientific Sessions educational experience. This unparalleled venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care.

Earn up to 35 Continuing Education Credits
Credit is available for physicians, family physicians, international physicians, podiatric physicians, nurses, pharmacists, psychologists, dietitians, and certified diabetes educators. Certificates of Completion/Attendance will be provided to registered attendees upon completion of the online evaluation.

Mini-Symposia (Formerly Meet-the-Expert Sessions)
Our new Mini-Symposia sessions will pique your interest from the very start of the meeting. These interactive sessions will feature 1-2 speakers presenting on a topic for 10-15 minutes with the remainder of the time devoted to questions and discussion with the audience. Mini-Symposia sessions will be held on Friday from 11:45 a.m. to 12:30 p.m. and 12:45 p.m. to 1:30 p.m.

Oral Presentations
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from over 380 original presentations highlighting the latest research and investigative methods not found at any other meeting.
Professional Interest Groups
Share your views during hot-topic discussions hosted by the Professional Interest Groups on the latest in research and care specific to your specialty. These interactive, lunch-time sessions are offered:

- Behavioral Medicine and Psychology
- Clinical Endocrinology, Health Care Delivery, and Public Health
- Diabetes Education
- Diabetes in Youth
- Epidemiology and Statistics
- Exercise
- Foot Care
- Nutritional Science and Metabolism
- Pregnancy and Reproductive Health

After the meeting, Interest Groups contribute to the Association in a variety of valuable ways throughout the year, with members serving on policy-making committees, writing technical reviews, writing position statements, and acting as liaisons with peer organizations. Visit professional.diabetes.org/interestgroups for the latest resources and information.

Product Theaters
Industry experts will provide insight into new diabetes services and products and demonstrate innovative equipment and technologies. Product Theaters will be conveniently scheduled during morning, lunch, and afternoon breaks in the Exhibit Hall on Saturday, Sunday, and Monday.

Product Theater content is the sole responsibility of the supporting company and is not part of the official education offered by the ADA at the Scientific Sessions.

Corporate Symposia
Corporate Symposia are satellite programs that are planned and conducted by the corporate community in conjunction with the Scientific Sessions. These programs provide attendees with additional education and information opportunities.

Pre-registered attendees will receive an e-mail on or about April 4, which will include instructions on registering for the Corporate Symposia. Attendees who register after April 4 will be able to select the Corporate Symposia when registering. All programs will take place at the Hilton New Orleans Riverside and the Sheraton New Orleans Hotel.

Visit scientificsessions.diabetes.org in early April for the most up-to-date schedule.

Corporate Symposia content is the sole responsibility of the supporting company and is not part of the official education offered by the ADA at the Scientific Sessions.

SPECIAL EVENTS
Opening Reception (Ticketed Event)
Join us in the convention center Friday evening from 6:30 p.m. to 8:30 p.m. for the Opening Reception. You won’t want to miss this taste of Mardi Gras complete with floats, a brass band, mask-making, and other fun N’awlins activities. Best of all, we’ll have live music that will entertain you and your friends with New Orleans funkiness mixed with a gumbo of soul and R&B for a high energy show to kick off your week in New Orleans. Healthy versions of New Orleans favorites, along with beverages, will be served.

5K@ADA Fun Run/Walk
The 5K@ADA Fun Run/Walk, supported by Novo Nordisk, will be held on Sunday morning at 6:30 a.m. Support the ADA Research Foundation by sporting a 5K@ADA running shirt available for $20 when you register for the meeting. A limited number of shirts will be available for purchase onsite for $25. Sign up for the Fun Run/Walk by visiting tracs.net/ADA5K. The event is free to all registered attendees.

Show Your True Colors—Support the American Diabetes Association by Wearing Red
Wear red on Sunday to show your support of the Association and our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Together, we can achieve a world free of diabetes and all its burdens.

Red merchandise is available for purchase in advance from shopdiabetes.org or onsite at the Shop Diabetes Store. Every purchase supports diabetes research, advocacy, awareness, and education programs.

CITY INFORMATION
New Orleans is the largest city in Louisiana overlooking the scenic Mississippi River. It’s famous for its blend of cultural influences and is known as the “Big Easy.”

Not sure where to start? Get yourself more acquainted with this diverse city by joining one of the many tours they have to offer. Whether you have a passion for the arts, a love for soulful food, or want to just wander and learn about the culture of New Orleans—there’s a wonderful tour waiting for you.

Some of the more popular tours are streetcar tours, history tours, and culinary tours. Streetcar tours will provide transportation to the Garden District, downtown, and a few other popular locations. History tours will allow you to learn about the monumental landmarks and the historical traditions that are embedded in New Orleans. Last but not least, culinary tours will give you the opportunity to delight in a variety of meals, as well as learn about how different cultures influenced all of the world-renowned New Orleans recipes.

There’s plenty to do in New Orleans, so come early or stay late and discover your favorite way to enjoy the Big Easy.
**REGISTRATION RATES**

<table>
<thead>
<tr>
<th></th>
<th>Member*</th>
<th>Non-Member</th>
<th>One-Day Member*</th>
<th>One-Day Non-Member</th>
<th>Student/Resident/Fellow</th>
<th>Guest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advance</td>
<td>February 26 - April 28</td>
<td>$530</td>
<td>$850</td>
<td>$310</td>
<td>$400</td>
<td>$290</td>
</tr>
<tr>
<td>Final</td>
<td>April 29 - June 14</td>
<td>$580</td>
<td>$900</td>
<td>$320</td>
<td>$410</td>
<td>$310</td>
</tr>
</tbody>
</table>

*In order to take advantage of the Member registration rate, your membership must be active at the time of registration through June 30, 2016.

**REGISTRATION CATEGORIES**

**Member**

Professional I and II Members. Have your Professional Member ID number available to register as a member. Professional Members who purchase a full meeting registration will receive free online access to the Scientific Sessions webcasts—*a $99 value!*

**Non-Member**

For those who are not ADA Professional I or II Members. Become a member when you register for the full meeting registration and save up to $320 off the Non-Member rate. You’ll also receive complimentary online access to the Scientific Sessions webcasts—*a $99 value!*

**One-Day**

Provides admittance to all sessions, including the Exhibit Hall and the Poster Hall (if open), for the selected day. You are allowed to register for only 1 One-Day Registration. One-Day registrants may not register guests.

**Student/Resident/Fellow**

Available to those currently enrolled in one of these programs. Proof of status in a program must be submitted in order to register.

**Guest**

You may register only one guest per full meeting registrant. Guest registration includes entrance to the Exhibit Hall, the Poster Hall, and non-ticketed social events only. Access to sessions is not permitted. Guests are not eligible for continuing education credit.

*Children under the age of 18, even if paid registrants, will not be admitted to session rooms, the Exhibit Hall or the Poster Hall. Exceptions will be made for nursing mothers as long as the child does not disrupt the session. For safety reasons, strollers are not allowed in session rooms, the Exhibit Hall, or the Poster Hall.*

**Register Online**

Go to scientificsessions.diabetes.org and click on the Registration Information tab.

Online registration is fast, easy, and secure. You will receive your confirmation letter and periodic updates via e-mail. If you are unable to register online, a downloadable registration form is available on the Scientific Sessions website.

Attendees should bring their confirmation letter with them onsite to receive their meeting materials. The barcode included on your confirmation letter will greatly speed you through registration. A picture ID will be required to pick up your registration materials.

**Questions?**

Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Or, visit the ADA Support Center at ada.cmrushelp.com.
**Advance Program**

**Media Registration**
Credentialed members of the media may register to attend the Scientific Sessions but are required to provide the ADA with a copy of their press credentials and letter of assignment prior to being confirmed. Qualified media outlets must represent the editorial staff, not the advertising or marketing staff. Publishers will not be considered as part of the editorial staff. Media registration is limited to 2 individuals per outlet.

Media interested in attending the meeting should submit their credentials to Samantha Boyd at sboyd@diabetes.org to request a complimentary registration. Go to scientificsessions.diabetes.org and click on the Media tab for more information.

**HOTEL INFORMATION**

**Book Online**
Go to scientificsessions.diabetes.org and click on the Hotel Information tab.

Reserving your room online allows you to see hotel availability in real time and allows us to send confirmation letters instantly. It also gives us a fast and easy way to contact you via e-mail with any changes or updates.

**Hotel Reservations**
Support the ADA by booking your hotel room within the Scientific Sessions housing block. In order to secure meeting and exhibit space necessary for the meeting, the ADA must book a minimum number of guest rooms in the city. You can help us avoid potential penalties by booking your room through our official housing company, CMR.

Hotel reservations can be made until May 13 based on availability. A listing of ADA meeting hotels, with rates and a locator map, is available at scientificsessions.diabetes.org. Reservations are available on a first-come, first-served basis. Reserve your room early for the best selection. All hotels require a credit card guarantee. If you are unable to reserve online, a downloadable housing form is available on the Scientific Sessions website.

**ADA Shuttle Bus Transportation**
Attendees who reserve their room within the Scientific Sessions housing block will receive a shuttle pass, enabling them to ride the ADA shuttle system at no additional cost.

Attendees who reserve their rooms through other means will not receive a shuttle pass. Shuttle passes will be available for purchase in advance through the online registration site and onsite at the meeting at a cost of $75 per person. The pass is valid throughout the duration of the meeting.

**International Group Organizers**
If you are organizing an international group (five or more rooms) to attend the Scientific Sessions, you may reserve your hotel rooms through our official housing company’s International Group Division, CMR’s Global Group Services website at ada-cmrglobalgroupservices.com, or contact them via e-mail at ada@cmr-globalgroupservices.com for an all-inclusive group housing package. For any questions regarding group registration, visit the ADA Support Center at ada.cmrushelp.com.

**Hotel Cancellations and Changes**
All requests for cancellations or changes can be made by going online or by contacting ADA’s official housing company. Changes received after May 13 will be subject to hotel availability. Reservations must be cancelled at least 72 hours prior to arrival to avoid penalty charges.

**Questions?**
Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 9:00 p.m. (Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +415-268-2086 (International). Or, visit the ADA Support Center at ada.cmrushelp.com.

**TRAVEL INFORMATION**

**Special Travel Discounts**
Traveling to the Scientific Sessions by plane or car? Check out the special discounts we have for you! Visit scientificsessions.diabetes.org and click on the Travel and Transportation Information tab for more information.

**Visa Requirements**
Attendees from outside the U.S. may need to apply for a visa at the American Embassy, consulate, or other visa issuing office in their country of origin. Please begin your visa application process as soon as possible, as it can take several months to receive approval.

If a letter of invitation is needed for your visa application, go to scientificsessions.diabetes.org and click on the Travel and Transportation Information tab to download the letter.
ACCREDITATION STATEMENTS

Physicians
The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Diabetes Association designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Family Physicians
An application for CME credit will be filed with the American Academy of Family Physicians.

Doctors of Osteopathy
Category 2 Credit will be awarded for formal educational programs that are ACCME-accredited or AAFP approved.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME for a recognized state medical society. Physician Assistants may receive a maximum of 35 hours of Category 1 Credit™ for completing this program.

Podiatric Physicians
An application for affiliate sponsorship will be filed with the American Podiatric Medical Association.

International Physicians
The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 credit(s)™.

European Union of Medical Specialists
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby: 1) European physicians attending an event in the USA had their credits recognized in Europe and 2) American physicians attending an event in Europe had their credits recognized in the USA.

The American Diabetes Association designates this educational activity for a maximum of 35 AMA PRA Category 1 Credit(s)™ for the American Diabetes Association’s 76th Scientific Sessions. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Nurses
The American Diabetes Association is accredited as a provider of continuing education by the American Nurses Credentialing Center’s COA.

California Board of Registered Nursing
The American Diabetes Association is a provider approved by the California Board of Registered Nursing. Provider No. CEP-12196. This activity is approved for 35 contact hours.

Dietitians
The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians will receive 35 continuing professional education units (CPEUs) for completion of this program/material.

Pharmacists
The American Diabetes Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Provider number 0239. The American Diabetes Association designates these sessions as Knowledge-based per ACPE guidelines. To view the UANs and learning objectives for each educational category, visit scientificsessions.diabetes.org and click on the Continuing Education tab.

Psychologists
The American Diabetes Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The American Diabetes Association maintains responsibility for the program and its content. This activity offers a maximum of 35 hours of continuing education credit. Each psychologist must attend in their entirety those sessions designated as offered for psychology credit and claim only those hours spent in the educational activity.

Certified Diabetes Educators
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.

Successful Completion Statement
Certificates of Completion/Attendance are provided to registered attendees based upon completion of the online evaluation. The online evaluation will be available at scientificsessions.diabetes.org from June 10 to July 15, 2016. For questions regarding continuing education, please e-mail professionaleducation@diabetes.org.
### Day-at-a-Glance Schedule
#### Friday, June 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 a.m.—12:30 p.m.</td>
<td><strong>Mini-Symposia</strong>&lt;br&gt;Recent Advances in Retinopathy—Have We Done Any Better?&lt;br&gt;New Technology and Diabetic Foot Ulcer Prevention&lt;br&gt;Dietary Guidelines for Americans&lt;br&gt;Causes and Maternal Consequences of Gestational Diabetes&lt;br&gt;Diabetes Camps for Kids—Update and Interactive Discussion&lt;br&gt;Pancreatic Pathology of Human Type 1 Diabetes&lt;br&gt;From Compliance to Empowerment—The Journey</td>
</tr>
<tr>
<td>12:45 p.m.—1:30 p.m.</td>
<td><strong>Mini-Symposia</strong>&lt;br&gt;Urologic Complications of Diabetes—Common, and Often Unaddressed&lt;br&gt;The Feasibility of Doing High-Intensity Interval Training (HIIT) in Persons with Diabetes&lt;br&gt;Patient-Centered Care—Is There Too Much of a Good Thing?&lt;br&gt;Recent Advances in the Genetics of Diabetic Nephropathy&lt;br&gt;Mitochondrial Dynamics in Metabolic Homeostasis</td>
</tr>
<tr>
<td>2:00 p.m.—4:00 p.m.</td>
<td><strong>Symposium</strong>&lt;br&gt;Clinical Models of Improving Kidney Outcomes within the Setting of Diabetes Care&lt;br&gt;Diabetes—Hope or Hype?&lt;br&gt;How Costs and Payments Impact Diabetes Care&lt;br&gt;Metformin Revisited 2016—New Insights, New Directions, Inpatient Management of Diabetes and Hyperglycemia—Novel Insights and Effective Approaches</td>
</tr>
<tr>
<td>4:15 p.m.—6:15 p.m.</td>
<td><strong>Symposium</strong>&lt;br&gt;Management of Cardiovascular Disease in the Patient with Diabetes—Basic Cardiology for the Diabetologist&lt;br&gt;State-of-the-Art Lecture&lt;br&gt;Joint ADA/ISPAD Symposium—Pediatric Diabetes Registries—What Do They Teach Us?&lt;br&gt;State-of-the-Art Lecture&lt;br&gt;Immunobiology of Type 2 Diabetes&lt;br&gt;Novel Experimental and Therapeutic Strategies to Target the Central Nervous System (CNS)-induced Regulation of Metabolism&lt;br&gt;State-of-the-Art Lecture&lt;br&gt;Oral Presentations</td>
</tr>
<tr>
<td>6:30 p.m.—8:30 p.m.</td>
<td><strong>Opening Reception</strong>—Ernest N. Morial Convention Center (Ticketed Event)</td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
</tr>
<tr>
<td>------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>8:00 a.m.—10:00 a.m.</td>
<td><strong>Symposia</strong></td>
</tr>
<tr>
<td>10:15 a.m.—11:15 a.m.</td>
<td>President, Health Care &amp; Education Address and Outstanding Educator in Diabetes Award Lecture</td>
</tr>
<tr>
<td>1:45 p.m.—3:45 p.m.</td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>4:00 p.m.—6:00 p.m.</td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Cutting through the Controversies in Fat, Protein, and Carb Counting in Type 1 Diabetes Technology and Diabetes Care—Your Patients Are Moving Forward—Are You Observing or Moving?</td>
<td>Current Status of Treatment of End Stage Renal Disease in Diabetes Heart Failure and Diabetes</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00 a.m. — 10:00 a.m.</td>
<td><strong>Symposia</strong> Hypoglycemia in Special Situations in Diabetes Morbidity and Mortality Conference for the Diabetic Foot — What Went Wrong and Why</td>
</tr>
<tr>
<td></td>
<td><strong>Symposia</strong> Peeling Back the Layers — Addressing Diabetes in the Context of Sub-cultural Influences NDEP Symposium — Moving Beyond Lip Service — Getting Serious about Diabetes Self-Management Education and Support</td>
</tr>
<tr>
<td></td>
<td><strong>Symposia</strong> Children with Type 1 Diabetes Are Not Little Adults — Differences in Pathophysiology Joint ADA/ASBMR Symposium — Sticks and Stones Can Break My Bones, but What about Diabetes? ADA Diabetes Symposium — Bioactive Lipids and Nonpeptide Mediators of Metabolism</td>
</tr>
<tr>
<td></td>
<td><strong>Symposium</strong> Regulation of Metabolic Flux and the Physiology of Insulin Resistance</td>
</tr>
<tr>
<td>10:15 a.m. — 11:45 a.m.</td>
<td><strong>Symposium</strong> The “Imitation Game” for Biology — Can We Break the Codes of Inter-organ Cross Talk and Win the War against Diabetes?</td>
</tr>
<tr>
<td>Noon — 2:00 p.m.</td>
<td>General Poster Session/Moderated Poster Discussions</td>
</tr>
<tr>
<td>12:30 p.m. — 1:45 p.m.</td>
<td>Professional Interest Group Discussions</td>
</tr>
<tr>
<td>2:15 p.m. — 4:15 p.m.</td>
<td><strong>Oral Presentations</strong> Edwin Bierman Award Lecture <strong>Symposium</strong> Crossing the Finish Line with Still Much to Accomplish — From Delivery to Day Care in Mothers with Diabetes Metabolic Surgery — Is It Ready for Prime Time? <strong>Symposium</strong> Kelly West Award for Outstanding Achievement in Epidemiology Lecture (2:15 p.m.—3:00 p.m.) <strong>Symposium</strong> Protecting the Beta Cell <strong>Oral Presentations</strong> Vivian Fonseca Scholar Award Presentation <strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>4:30 p.m. — 6:30 p.m.</td>
<td><strong>Symposium</strong> Targeting PCSK9 for Treatment of Hyperlipidemia — Progress and Controversies <strong>Oral Presentations</strong> State-of-the-Art Lecture <strong>Symposium</strong> The Future of Quality Measurement — Metrics that Matter The New Face of Injectable Options Addressing Obesity and Metabolic Disturbances in a Meaningful Way — Are We There Yet? The Role of Continuous Glucose Monitoring in Diabetes Management <strong>Symposium</strong> Diabetes and Precision Medicine — What Can We Learn about Diabetes with “Omics”? <strong>Symposium</strong> Insulin Resistance — What We Know and Don’t Know <strong>Symposium</strong> Beyond Taste — Various Functions of Extracel “Taste” Receptors <strong>Symposium</strong> Autocrine and Paracrine Signaling between Islet Cell Types</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8:00 a.m.—10:00 a.m.</td>
<td>Symposium: Joint ADA/ASN Symposium—Innovations in Treating Inflammation for Diabetic Kidney Disease</td>
</tr>
<tr>
<td></td>
<td>Symposium: Deconstructing Cellular Heterogeneity in Diabetes-relevant Tissues</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>10:15 a.m.—11:45 a.m.</td>
<td>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture</td>
</tr>
<tr>
<td>Noon—2:00 p.m.</td>
<td>General Poster Session/Moderated Poster Discussions</td>
</tr>
<tr>
<td>12:30 p.m.—1:45 p.m.</td>
<td>Professional Interest Group Discussions</td>
</tr>
<tr>
<td>2:15 p.m.—4:15 p.m.</td>
<td>Symposium: Hypoglycemic Disorders Oral Presentations</td>
</tr>
<tr>
<td></td>
<td>Symposium: In Response to the Tsunami—New Models of Care to More Effectively Treat Gestational Diabetes Mellitus and Maternal Obesity Joint ADA/JDRF Symposium—Optimizing Use of Technology and Therapeutics in Pediatric Diabetes Results of the Liraglutide Effect and Action in Diabetes—Evaluation of Cardiovascular Outcome Results (LEADER) Trial</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
</tr>
<tr>
<td>4:30 p.m.—6:30 p.m.</td>
<td>Symposium: Therapy of Diabetic Neuropathy—We Can Do Better Oral Presentations</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
</tr>
<tr>
<td></td>
<td>Oral Presentations</td>
</tr>
</tbody>
</table>
### DAY-AT-A-GLANCE SCHEDULE
#### TUESDAY, JUNE 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.—10:00 a.m.</td>
<td><strong>Symposium</strong> Microbiota, Inflammation, and Diabetic Cardiovascular Disease</td>
<td><strong>Symposium</strong> Moving On Up—Transition to Adulthood and Adult Care for Young Adults with Type 1 Diabetes</td>
<td><strong>Symposium</strong> Update from the EMPA-REG Outcome Trial</td>
<td><strong>Symposium</strong> Epidemiology of Kidney Disease in Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 a.m.—12:15 p.m.</td>
<td></td>
<td><strong>Oral Presentations</strong> ADA Presidents Oral Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SECTIONS

FRIDAY, JUNE 10

11:45 a.m.–12:30 p.m.
Mini-Symposia Sessions
- Recent Advances in Retinopathy—Have We Done Any Better?
  Diabetes and Neuroretina—What Have We Learned from Human Patients/Donors?
  Patrice E. Fort, PhD
  Blocking Wnt Signaling—A New Strategy for the Treatment of Diabetic Retinopathy
  Jian-Xiang, Ma, MD, PhD
  Question and Discussion Period

- New Technology and Diabetic Foot Ulcer Prevention
  Diabetic Foot Ulcer Prevention Technology—The Latest Updates and Research
  Bijan Najafi, PhD, MSc
  Question and Discussion Period

- Dietary Guidelines for Americans
  The Evidence and Politics of the Dietary Guidelines for Americans
  Frank B. Hu, MD, PhD
  Question and Discussion Period

- Causes and Maternal Consequences of Gestational Diabetes
  Is the Inevitable Really Inevitable? Protecting Mom from Diabetes after Pregnancy
  Thomas A. Buchanan, MD
  Question and Discussion Period

- Diabetes Camps for Kids—Update and Interactive Discussion
  ADA and Diabetes Camps
  Anisha S. Dharshi, MPH
  International Diabetes Camps
  Nicolas Cuttriss, MD, MPH, FAAP
  Question and Discussion Period

- Pancreatic Pathology of Human Type 1 Diabetes
  Is nPOD Still Cutting Edge?
  Alberto Pugliese, MD
  Question and Discussion Period

12:45 p.m.–1:30 p.m.
Mini-Symposia Sessions
- Urologic Complications of Diabetes—Common, and Often Unaddressed
  Urologic Complications of Diabetes—Common, and Often Unaddressed
  Tamara G. Bavendam, MD, MS
  Question and Discussion Period

- The Feasibility of Doing High-Intensity Interval Training (HIIT) in Persons with Diabetes
  To HIIT or Not to HIIT?
  Sheri R. Colberg-Ochs, PhD
  Question and Discussion Period

- From Compliance to Empowerment—The Journey
  How My Hatred of School Led to a Passionate Commitment to Patient Empowerment
  Robert M. Anderson, EdD

- Patient-Centered Care—Is There Too Much of a Good Thing?
  Advantages
  Rene Rodriguez-Gutierrez, MD, MSc
  Challenges
  Philip Raskin, MD, FACP, FACE, CDE
  Question and Discussion Period

- Recent Advances in the Genetics of Diabetic Nephropathy
  A Genome-Wide Analysis of Nephropathy Risk in Type 1 Diabetes—The JDRF Diabetic Nephropathy Collaborative Initiative
  Stephen S. Rich, PhD
  Genetics of Diabetic Kidney Disease in Type 1 and Type 2 Diabetes—Insights from the SUMMIT Project
  Mark I. McCarthy, MD
  Question and Discussion Period

2:00 p.m.–4:00 p.m.
Symposia
- Clinical Models of Improving Kidney Outcomes within the Setting of Diabetes Care
  Innovative Approaches in the Veterans Administration
  Adriana M. Hung, MD, MPH
  Population Health Approaches to Improving Care in Underserved Settings
  Yoshio N. Hall, MD, MS
  ICD-Pieces, a Pragmatic Trial of Patients with Multiple Chronic Conditions
  Miguel A. Vazquez, MD

- Digital Health in Diabetes—Hope or Hype?
  Is Transforming Diabetes Possible? Lessons from Participatory Design of Digital Health Solutions
  Joyce M. Lee, MD, MPH
  Lessons Learned—A Clinician’s Perspective on Digital Diabetes Care
  Howard A. Wolpert, MD
  Digital Health and Diabetes—Where We’re Going and Why It Matters
  Chris Bergstrom, MBA
  Question and Discussion Period

- Follow the Money—How Costs and Payments Impact Diabetes Care
  Value-based Reimbursement
  Robert A. Gabbay, MD, PhD

Speakers and presentation titles are subject to change.
Advance Program

• Metformin Revisited 2016—New Insights, New Directions
  Metformin and the Gut—New Insights into Gut-Based Mechanisms of Metformin—Physiology and Therapeutic Implications
  Clifford J. Bailey, PhD, FRCP Edin, FRCPath
  Metformin and the Heart—What Do We Know?
  Rury R. Holman, FRCP, FMedSci
  Clinical Controversies—Use of Metformin in Patients with Reduced Kidney Function—Current Data
  Kasia J. Lipska, MD, MHS
  Repurposing Metformin—Metformin and Cancer Risk and Mortality
  Michael Pollak, MD

• Inpatient Management of Diabetes and Hyperglycemia—Novel Insights and Effective Approaches
  Glucometrics for Measuring Inpatient Glycemic Outcomes—Definition, Implementation, and Benchmarks
  Curtiss B. Cook, MD
  Effective Alternatives for the Treatment of DKA—IV vs. SQ, Admission vs. Observation
  Guillermo E. Umpierrez, MD, FACP, FACE
  Automating Insulin Dosing Decisions—Benefits, Limitations, and Cost Effectiveness
  Thomas R. Pieber, MD
  Remote Monitoring of and Support for Inpatient Diabetes Management through the Inpatient EMR
  Robert J. Rushakoff, MD, MS
  Effective Transition from IV to SQ Insulin Therapy—Best Practices and Tricks of the Trade
  David Baldwin, MD
  Question and Discussion Period

• Disparities and the Social Epidemiology of Diabetes—A Multi-level Approach
  The Current State of Diabetes Disparities—An Overview
  Leonard E. Egede, MD, MS
  Food Insecurity, Housing Instability, and Material Deprivation—The Epidemiology of Unmet Basic Needs in Diabetes
  John Billimek, PhD
  Interpersonal Factors in Diabetes Disparities—The Role of the Family, Peers, and Communication
  Michele Heisler, MD, MPA
  Neighborhood Factors in Diabetes Disparities
  Arlene F. Brown, MD, PhD

• Update on Cell Sources for Beta-Cell Replacement
  Beta-Cell Replacement in Type 1 Diabetes—Consideration in Design of Clinical Trials
  Bruce S. Schneider, MD
  Pig Islet Xenotransplantation
  David K.C. Cooper, MD, PhD, FRCS
  Pluripotent Stem Cell-derived Beta Cells
  Dietrich Egli, PhD
  Gene Editing
  Chad A. Cowan, PhD

• Metabolism and Immunity in Insulin Action
  Linking Metabolism and the Immune Response
  Anthony W. Ferrante, Jr., MD, PhD
  Uncoupling Lipid Metabolism from Inflammation
  David A. Bernlohr, PhD
  Inflammatory Remarks on the Regulation of Metabolism
  Owen P. McGuinness, PhD
  Immune Response to Loss of Metabolic Regulation due to Impaired Lipolysis
  Erin E. Kershaw, MD

• FTO Brought Up-to-Date—The FTO Gene Locus in Obesity
  FTO—Overview and Link to Leptin Resistance
  Giles Yeo, PhD
  The Role of Cilia in Obesity Associated with the FTO Locus
  George Stratigopoulos, PhD
  Variable Influence of FTO on BMI across Birth Cohorts
  James Niels Rosenquist, MD, PhD
  The Role of the FTO Obesity Risk Locus in Browning of Human Fat
  Melina Claussnitzer, PhD

• New Imaging Approaches to Assess Functional Beta-Cell Characteristics
  Imaging Submembrane cAMP Dynamics in the Beta Cell
  Anders Tengholm, PhD
  Characterizing Beta-Cell Heterogeneity and Dysfunction Using Optogenetics
  Richard K.P. Benninger, PhD
  Endocrine Cell Distribution throughout Whole Human Pancreata
  Manami Hara, DDS, PhD
  Ex Vivo Imaging of Islet Metabolism Using NAD(P)H, FLIM, and FRET
  Matthew J. Merrins, PhD

4:15 p.m.–6:15 p.m.

Symposia

• Management of Cardiovascular Disease in the Patient with Diabetes—Basic Cardiology for the Diabetologist
  Management of Unstable Angina and Myocardial Infarction in the Patient with Diabetes
  Yochai Birnbaum, MD, FAHA, FACC
  Management of Heart Failure in the Patient with Diabetes
  Mikhail N. Kosiborod, MD
  Management of Peripheral Artery Disease in the Patient with Diabetes—A Vascular Surgeon’s Perspective
  William C. Pevec, MD
  Management of Hypertension in the Patient with Diabetes
  William C. Cushman, MD
• Joint ADA/ISPAD Symposium—Pediatric Diabetes Registries—What Do They Teach Us?
Past, Present, and Future of Pediatric Diabetes Registries
Elizabeth Mayer-Davis, PhD
SWEET—Improving Health in Pediatric Diabetes Worldwide
Thomas Danne, MD, PhD
DPV—Registries as Structure for Quality Improvement
Reinhard W. Holl, MD, PhD
The Type 1 Diabetes Exchange—From Registry to Clinical Trials
Kellee M. Miller, PhD

• Immunobiology of Type 2 Diabetes
Dendritic Cells, Inflammation, and Diabetes
Kristin V. Tarbell, PhD
Potential Roles of Inflammation in Type 2 Diabetes
Steven E. Shoelson, MD, PhD
T Cell Inflammation in Human Obesity and Type 2 Diabetes
Barbara S. Nikolajczyk, PhD
iNK T Cells and Metabolic Syndrome
Mark A. Exley, PhD

• Novel Experimental and Therapeutic Strategies to Target the Central Nervous System (CNS)-induced Regulation of Metabolism
Using Optogenetics to Understand CNS Glucoregulation
Gregory J. Morton, PhD
Intranasal Insulin and Regulation of Endogenous Glucose Production
Satya Dash, MD, PhD, FRCPC
Multi-agonism Therapeutic Strategies to CNS Regulation of Energy Homeostasis
Brian Finan, PhD
Radio- and Magnetogenetics as a Tool for Understanding Glucose Regulation
Sarah A. Stanley, MB, BChir, PhD

Oral Presentations
• State-of-the-Art Lectures

6:30 p.m.–8:30 p.m.
• Opening Reception—Ernest N. Morial Convention Center (Ticketed Event)

SATURDAY, JUNE 11
8:00 a.m.–10:00 a.m.
Symposia
• Paradigm Shifts in Diabetic Kidney Disease
Diagnosis of Diabetic Kidney Disease—More than Albuminuria?
Amy K. Mottl, MD, MPH
How Much of End-Stage Renal Disease is Attributable to Diabetes?
Kevin C. Abbott, MD, MPH
Diabetes and Chronic Kidney Disease—Lessons from the Chronic Renal Insufficiency Cohort Study
Harold I. Feldman, MD, MSCE
Diabetic Kidney Disease Goes Global—Impact on Health in Latin America
Rafael Lozano, MD

• International Perspectives on Treatment of the Diabetic Foot—A Walk Across the World
The Diabetic Foot in South America—The Brazilian Experience
Hermelinda C. Pedrosa, MD
The Diabetic Foot—A Perspective from India
Vijay Viswanathan, MD, PhD, FRCP
The European Perspective—Diabetic Foot Treatment in the Netherlands
Nicolaas C. Schaper, MD, PhD
Diabetic Foot Limb Salvage Case Presentation and Group Discussion
Nicholas J. Lowery, DPM
Hermelinda C. Pedrosa, MD
Vijay Viswanathan, MD, PhD, FRCP
Nicolaas C. Schaper, MD, PhD

• ADA Education Recognition Program Symposium—How to Succeed at Diabetes Self-Management Education (DSME)
Tapping Internal and External Resources Strengthens DSME Reach
Kathryn Parker, RD, LD/N
Advancing Diabetic Care from Hospital to Outpatient DSME Using Innovation and Cross-Departmental Collaboration
Nancy Talio, RN, CDE
Increasing Access to DSME in Rural and Underserved Populations
Dietrich Taylor, RN, CDE
Question and Discussion Period

• What’s New in Exercise-mediated Glucose Transport in Skeletal Muscle?
Novel, Single Muscle Fiber Analysis Reveals Exercise Effects on Glucose Uptake
Gregory D. Cartee, PhD
Rac1—A Novel Regulator of Contraction-stimulated Glucose Uptake in Skeletal Muscle
Thomas E. Jensen, PhD
Calmodulin Kinase and Exercise-regulated Glucose Metabolism in Skeletal Muscle
Juleen R. Zierath, PhD

• ADA Diabetes Care Symposium—Novel Translational Strategies in the Management of Diabetes
Session information not available at time of printing.
Advance Program

• This Is How You Do It—Medication Options, Sequence, and Combinations for Optimal Management of Type 2 Diabetes
  Starting a GLP-1 RA after Metformin
  Pablo F. Mora, MD, MSc, FACE, CDE
  Starting SGLT2 Inhibitors before Incretin Therapies—Is Empagliflozin a Game Changer?
  Fernando Ovalle, MD
  Using Combination Approaches—Incretin Plus SGLT2i when Metformin Is No Longer Sufficient
  Ildiko Lingvay, MD, MPH, MSCS
  Insulin Remains the Safest Alternative after Metformin
  Alice YY. Cheng, MD, FRCPC
  Bringing It All Together—What the Objective Clinician Should Do
  Christopher H. Sorli, MD, PhD, FACE
  Question and Discussion Period

• Issues Facing Clinical Beta Cell Replacement—Now and Later
  Wait-List Considerations and Transplant Options for Type 1 Diabetes
  Andrew M. Posselt, MD, PhD
  Type 2 Diabetes as a Target for Pancreas and Islet Transplantation
  John L. Leahy, MD
  Why Are So Few Islet Transplants Currently Being Done for Type 1 Diabetes?
  Camillo Ricordi, MD
  Islet Transplantation after Pancreatectomy for Chronic Pancreatitis—Mixed Blessings
  R. Paul Robertson, MD

• Intermediary Metabolites and Insulin Action
  Novel Mechanisms of Insulin Sensitization by Dietary Methionine Restriction
  Thomas W. Gettys, PhD
  Acylcarnitines, Insulin Resistance, and Cell Stress Responses
  Sean H. Adams, PhD
  Circulating Redox State
  Barbara E. Corkey, PhD
  Intermediary Metabolism of Monocarboxylates
  Eric B. Taylor, PhD

• Cognitive Control of Eating and Body Weight
  A View of Obesity as a Learning and Memory Disorder
  Terry L. Davidson, PhD
  Feeding Potentiated by Environmental Cues
  Gorica D. Petrovich, PhD
  Cognitive Factors Controlling Meal Size and Satiety
  Jeff M. Brunstrom, BSc, MSc, PhD
  Forebrain Circuity Leading to Obesity
  Alexxai V. Kravitz, PhD

Oral Presentations
10:15 a.m.–11:15 a.m.
• President, Health Care & Education Address
  Margaret A. Powers, PhD, RD, CDE
• Outstanding Educator in Diabetes Award Lecture
  Sheri R. Colberg-Ochs, PhD

11:30 a.m.–1:30 p.m.
• General Poster Session/Moderated Poster Discussions

Noon–1:15 p.m.
• Professional Interest Group Discussions

1:45 p.m.–3:45 p.m.
Symposia
• New Advances in Diabetic Retinopathy—What Wikipedia Can’t Tell You
  Decoding Diabetic Retinopathy—What Epigenetics Can Teach Us
  Renu A. Kowluru, PhD
  Lipid-Lowering Treatments and Diabetic Retinopathy—A Lipocentric Approach to a Glucocentric Problem
  Emily Y. Chew, MD
  What Have We Learned from the Anti-VEGF Clinical Trials?
  Arup Das, MD, PhD
  In Vivo Retinal Imaging in Diabetic Individuals
  Susanna S. Park, MD, PhD
  Stem Cell Treatment Opportunities for Diabetic Eye Disease
  Alexander V. Ljubimov, PhD
  Question and Discussion Period

• Beyond A1c—Why Quality of Life Matters (with Richard R. Rubin Award Lecture)
  Richard R. Rubin Award Lecture
  Elizabeth A. Walker, PhD, RN
  Developing a Measure of Diabetes Health-related Quality of Life across the Lifespan—Preliminary Qualitative Findings
  Marisa E. Hilliard, PhD
  Quality of Life—Issues of Conceptualization and Measurement
  Lawrence Fisher, PhD

• Diabetes Self-Management Education and Support in Type 2 Diabetes—Joint Position Statement of the ADA, AADE, and AND
  Diabetes Self-Management Education and Support—Benefits, Challenges, and Achieving Performance Measures
  Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDE
  Four Critical Times to Assess, Provide, and Adjust Diabetes Self-Management Education and Support
  Nisha A. Basu, MD, MPH
  Guiding Principles and Key Elements of Initial and Ongoing Diabetes Self-Management Education and Support
  Martha M. Funnell, MS, RN, CDE
  Implementing the Diabetes Self-Management Education and Support Algorithm of Care—Models for Delivery
  Eva M. Vivian, PharmD, MS
• Can Antenatal Lifestyle Interventions Improve Pregnancy Outcomes or Is It Too Little, Too Late?
  Yes—Interventions Hold Promise
  William C. Knowler, MD, DrPH
  No—Interventions to Prevent Gestational Diabetes Mellitus Are Destined for Failure
  David Simmons, MD
  Intervention Successes or Failures—Fetal Reasons
  Christopher J. Nolan, PhD, FRACP
  Intervention Successes or Failures—Maternal Reasons
  H. David McIntyre, MD, FRACP
  Panel Discussion—Necessary Timing and Intensity to Alter Pregnancy Outcomes—Where Do We Go from Here?
  Patrick M. Catalano, MD
  Gernot Desoye, PhD

• The Good Heart, the Bad Bone, and the Ugly Alpha Cell—What About Them SGLT2 Inhibitors?
  SGLT2 Inhibitor Effect on Blood Pressure, Body Weight, and Fat Distribution
  Sunder Mudaliar, MD, FRCP Edin, FACP, FACE
  Potential Benefits of SGLT2 Antagonists in Prevention and Safety of Use in Patients with Heart Failure
  David Aguilar, MD
  Bone Health and SGLT2 Inhibitors—Direct Effect or Not-So-Innocent Bystander?
  Naim M. Maalouf, MD
  Understanding the Risk of DKA when Hyperglycemia Is Treated with SGLT2 Inhibitors
  Simeon I. Taylor, MD, PhD

• New Challenges in Adolescents and Young Adults with Type 2 Diabetes
  Summary of the ADA Type 2 Diabetes in Youth Consensus Conference
  Kristen J. Nadeau, MD, MS
  New Insights on Genetics of Type 2 Diabetes
  Jose C. Florez, MD, PhD
  Pregnancy in Type 2 Diabetes Adolescents and Young Adults
  Robin S. Goland, MD
  Transition of Adolescent Type 2 Diabetes Patients to Adult Care
  Catherine Pihoker, MD

• Real-Life and Realistic Evidence from Pragmatic Studies and Natural Experiments in Diabetes
  Pragmatic Studies and Natural Experiments—How They Differ from Traditional Epidemiological Studies, and Their Value
  Julie A. Schmidtdiel, PhD
  Expansion (or Contraction) of Health System and Insurance Models that Impact Diabetes Care
  O. Kenrik Duru, MD
  Novel Approaches to Assess Policy Interventions to Reduce Diabetes and Cardiovascular Incidence (e.g., Taxes, Subsidies, and Neighborhood-wide Interventions)
  Sanjay Basu, MD, PhD
  Carrots and Sticks—Does Incentivizing Healthy Behaviors (or Disincentivizing Unhealthy Choices) Work to Improve Diabetes Risk?
  Ronald T. Ackermann, MD, MPH

• Immune Cell Metabolic Demand
  Bioenergetics and Extracellular ATP in Immune Cell Activation
  Wolfgang Junger, PhD
  Metabolic Regulation of T Cells
  Hongbo Chi, PhD
  Dendritic Cell Bioenergetics and Immunity
  Edward J. Pearce, PhD
  T Cell Metabolism in Autoimmunity
  Laurence M. Morel, PhD

• Modeling Human Disease Variants in the Beta Cell
  Using EndoC-β Cells to Model Diabetes
  Raphael Scharffmann, PhD
  Modeling Type 1 Diabetes in Human-Induced Pluripotent Stem Cells
  Rohit N. Kulkarni, MD, PhD
  Gene Editing in Human ES Cells to Study Pancreatic Development and Diabetes
  Danwei Huangfu, PhD
  Role of GATA6 in Human Endoderm and Pancreatic Development
  Paul Gadue, PhD

• Immunology
  Cutting through the Controversies in Fat, Protein, and Carb Counting in Type 1 Diabetes
  The Physiology of How and Why Fat and Protein Matter
  Amir Shafat, BSc, PhD
  Use of Metabolic Models to Optimize Insulin Dose Adjustments for Fat and Protein
  Garry M. Steil, PhD
  Fat, Protein, and Carb Counting—A European Approach
  Olga Kordonouri, MD
  Counting the Fat, Protein, and Carbs—Translating the Evidence into Clinical Practice
  Carmel E. Smart, RD, PhD

• Technology and Diabetes Care—Your Patients Are Moving Forward—Are You Observing or Moving?
  Is There a Need and What Can Be Learned from On-Line Diabetes Communities?
  Anna Floreen
  Telemedicine—An Engine for Team Activation
  Jodi Krall, PhD
  Make the Data Work for You—Increasing Accessibility, Integration, and Usability of Ambulatory Glucose Profiles
  Deborah M. Mullen, PhD
  Don’t Let Technology Slow You Down—What You Need to Know When Your Patients Use Apps
  Jennifer C. Smith, RD, LD, CDE

Speakers and presentation titles are subject to change.
Advance Program

- Current Status of Treatment of End Stage Renal Disease in Diabetes
  Adequacy of Hemodialysis
  Allen M. Kaufman, MD
  Peritoneal Dialysis
  Fredric O. Finkelstein, MD
  Forms of Home Dialysis
  Anjay Rastogi, MD, PhD
  Renal Transplantation
  Warren L. Kupin, MD, FACP

- Heart Failure and Diabetes
  Natural History, Clinical Manifestations, and Pathophysiology/Mechanism of Heart Failure in Patients with Diabetes
  Eberhard Standl, MD, PhD, FESC
  Impact of Specific Antiglycemic Therapies on Heart Failure Risk
  Steven P. Marso, MD
  GLP-1 RA and Cardiovascular Physiology—Will the Clinic Ever Confirm the Mechanistic Studies?
  Mansoor Husain, MD, FRCPC

- Leveraging Genetics in Clinical Practice
  Etiologic Heterogeneity of Diabetes in Young Adults
  Celeste C. Thomas, MD, MS
  Genetic Testing for MODY—A Patient’s Perspective
  Jennifer Rice, MBA
  Economics of Personalized Medicine/Health Insurance Reimbursement of Genetic Testing
  Kathryn A. Phillips, PhD
  The Personalized Diabetes Medicine Program
  Toni I. Pollin, PhD

- Shared Mechanisms of Diabetes, Cancer, and Aging
  The mTOR Signaling Network and Metabolic Regulation
  Brendan D. Manning, PhD
  AMPK Signaling in Diabetes and Cancer
  Reuben J. Shaw, PhD
  FGF-21, Metabolism, and Aging
  Steven Kliewer, PhD
  Shared Themes of Metabolic Regulation
  Ralph J. Deberardinis, MD, PhD

- All Things In-between—The Extracellular Matrix and Insulin Resistance
  Coupling of ECM Remodeling to Insulin Resistance—Role of Integrin Receptor Signaling
  David H. Wasserman, PhD
  Extracellular Matrix, Adipose Tissue, and Insulin Resistance
  Philip A. Kern, MD
  Extracellular Matrix, Skeletal Muscle, and Insulin Resistance
  David Cameron-Smith, PhD
  Effects of Weight Gain or Loss on Extracellular Matrix on Adipose, Muscle, and Liver
  Kai Sun, MD, PhD

- Organelle Dynamics and the Control of Insulin Secretion
  Wolfram Syndrome—A Prototype of Impaired Insulin Production due to Endoplasmic Reticulum Dysfunction
  Fumihiko Urano, MD, PhD
  Roles of Microtubule Architecture and Dynamics in Regulation of Insulin Secretion
  Irina Kaverina, PhD
  Insulin Granule Heterogeneity and Stimulated Secretion
  Michele Solimena, MD, PhD
  Balancing Insulin Granule Degradation and Secretion in Functional Beta Cells
  Romeo Ricci, MD

Oral Presentations
- Roger Pecoraro Award Lecture
  Nicolaas C. Schaper, MD, PhD

- Norbert Freinkel Award Lecture
  H. David McIntyre, MD, FRACP

SUNDAY, JUNE 12
WEAR RED DAY
8:00 a.m.–10:00 a.m.

Symposia
- Hypoglycemia in Special Situations in Diabetes
  Exercise and Hypoglycemia
  Stephen N. Davis, MD
  Factors Affecting Hypoglycemia in Children
  William V. Tamborlane, MD
  Gastroparesis and Hypoglycemia
  Michael Horowitz, MBBS, PhD

- Morbidity and Mortality Conference for the Diabetic Foot—What Went Wrong and Why
  Complicated Cases of Charcot Neuroarthropathy
  George T. Liu, DPM
  Complications of Vascular Intervention and Diabetic Limb Salvage
  Misaki Kiguchi, MD
  Complications and Infection Cases of the Diabetic Foot
  Mark Abbruzzese, MD
  Challenging Cases of Diabetic Foot Ulceration Complications
  Andrew J.M. Boulton, MD, DSc, FACP, FRCP

- Peeling Back the Layers—Addressing Diabetes in the Context of Sub-cultural Influences
  Differences in Diabetes Prevalence and Outcomes across U.S. Hispanic Subgroups
  Neil Schneiderman, PhD
  Is “Asian” a Meaningful Category for Studying and Reporting Disparities?
  Nadia Islam, PhD
  Diabetes among Migrant South Asians
  Kamlesh Khunti, PhD, MD, FRCP, FRCP
  Addressing Diabetes in American Indian and Alaska Native Communities
  Yvette Roubideaux, MD, MPH
• NDEP Symposium—Moving Beyond Lip Service—Getting Serious about Diabetes Self-Management Education and Support
  Introduction
  Judith A. McDivitt, PhD
  Is Diabetes Education Broken? If So, How Do We Fix It?
  Linda M. Siminerio, RN, PhD, CDE
  The Future of Self-Management—What’s Emerging from NIH Research?
  Judith E. Fradkin, MD
  Delivering Diabetes Education Programs by Linking the Clinical and Community Sectors—What’s Working?
  Ann L. Albright, PhD, RD
  NDEP Resources to Support Diabetes Self-Management Education and Support Programs
  Joanne M. Gallivan, MS, RDN
  Conclusions
  Linda M. Siminerio, RN, PhD, CDE

• Children with Type 1 Diabetes Are Not Little Adults—Differences in Pathophysiology
  Differences between Pediatric and Adult Onset Type 1 Diabetes—Pathophysiology Prediagnosis
  Peter A. Gottlieb, MD
  Differences between Pediatric and Adult Onset Type 1 Diabetes—C-Peptide Loss Postdiagnosis
  Carla J. Greenbaum, MD
  Differences in Development of Disease-Modifying Strategies in Children with Type 1 Diabetes
  Diane K. Wherrett, MD, FRCP
  Complications—Morbidity/Mortality in those Diagnosed as Children
  Kim C. Donaghue, MBBS, PhD, FRACP

• Joint ADA/ASBMR Symposium—Sticks and Stones Can Break My Bones, but What about Diabetes?
  The Effects of Type 1 and Type 2 Diabetes on the Skeleton
  Ann V. Schwartz, PhD
  The Effects of the Skeleton on Glucose Homeostasis
  Stavroula Kousteni, PhD
  Effects of Diabetes Therapeutics on Bone Health
  Steven E. Kahn, MB, ChB
  Clinical Management of Fracture Risk in Patients with Diabetes
  Sundeep Khosla, MD

• ADA Diabetes Symposium—Bioactive Lipids and Nonpeptide Mediators of Metabolism
  RNA Regulation of Lipotoxicity
  Jean E. Schaffer, MD
  Metabolic Benefits of Phospholipid Activation of NR5A Nuclear Receptors
  David D. Moore, PhD
  Impact of Branched Fatty Acid Esters of Hydroxy Fatty Acids on Metabolic and Inflammatory Diseases
  Ismail Syed, PhD
  De Novo Lipogenesis Products and Palmetoleate in Systemic Immunometabolism
  Gökhan S. Hotamisligil, MD, PhD

• Regulation of Metabolic Flux and the Physiology of Insulin Resistance
  Novel Stable Isotope Methods to Determine Metabolic Fluxes In Vivo
  Peter Crawford, MD, PhD
  Dysregulated Oxidative Flux during Insulin Resistance
  Jamey D. Young, PhD
  Unveiling Novel Mechanisms of Disease by Metabolomic Approaches
  Alan Saghatelian, PhD
  Intrinsic Control of Metabolic Flux during Diabetes
  Albert K. Groen, PhD

• The “Imitation Game” for Biology—Can We Break the Codes of Inter-organ Cross Talk and Win the War against Diabetes?
  The Gut-Brain Axis for Metabolic Control
  Tony K.T. Lam, PhD
  The Brain-Liver Axis—What Is the Evidence in Humans?
  Meredith A. Hawkins, MD
  Adipocyte-Muscle-Liver Cross Talk and Regulation of Metabolism
  Vanessa Pellegrinelli, PhD
  Intervening with Inter-organ Cross Talk—The Next Frontier in Therapeutics?
  Randy J. Seeley, PhD

• Joint ADA/EASD Symposium—Beta-Cell Heterogeneity—are Some Cells More Equal than Others?
  Beta-Cell Heterogeneity in the Islet of Langerhans
  Heiko Lickert, PhD
  Islet Vascular Heterogeneity
  Per-Ola Carlsson, MD, PhD
  Measuring Functional Heterogeneity in Beta Cells
  Wen-hong Li, PhD
  Beta-Cell Cell Surface Molecules Reveal Different Subpopulations
  Philip R. Streeter, PhD

Oral Presentations
10:15 a.m.–11:45 a.m.
• President, Medicine & Science Address
  Desmond Schatz, MD
• Banting Medal for Scientific Achievement
  Barbara B. Kahn, MD

Noon–2:00 p.m.
• General Poster Session/ Moderated Poster Discussions

Speakers and presentation titles are subject to change.
12:30 p.m.–1:45 p.m.
• Professional Interest Group Discussions

2:15 p.m.–3:00 p.m.
• Kelly West Award for Outstanding Achievement in Epidemiology Lecture
  Edward W. Gregg, PhD

2:15 p.m.–4:15 p.m.
Symposia
• Crossing the Finish Line with Still Much to Accomplish—From Delivery to Day Care in Mothers with Diabetes
  Insulin Pumps and Closed Loop Systems to Replace Insulin Drips at Labor and Delivery
  Helen R. Murphy, MD, FRACP
  Long-Acting Reversible Contraception (LARC) before Taking the Baby Home
  Stephanie Teal, MD, MPH
  New Trials Demonstrating the Power of Lactation to Prevent Type 2 Diabetes Mellitus
  Erica P. Gunderson, PhD, MS, MPH
  More Effective Postpartum Strategies to Assess/Prevent Future Diabetes Risk
  Erin Keely, MD, FRCPC

• Metabolic Surgery—Is It Ready for Prime Time?
  What Is the Evidence in Support of Metabolic Surgery for the Treatment of Type 2 Diabetes?
  Philip R. Schauer, MD
  What Are the Evidence Gaps in Support of Metabolic Surgery for the Treatment of Type 2 Diabetes?
  David M. Nathan, MD
  What Is the Cost Effectiveness of Metabolic Surgery for the Treatment of Type 2 Diabetes?
  William H. Herman, MD, MPH
  What Are the Policy Implications of Metabolic Surgery for the Treatment of Type 2 Diabetes?
  Richard W. Grant, MD, MPH

• Protecting the Beta Cell
  Autoimmunity
  Mark S. Anderson, MD, PhD
  Encapsulation
  Girish Chitnis, PhD
  Scaffolds
  Lonnie D. Shea, PhD
  Next-Generation Islet Grafts
  Jose Oberholzer, MD
  Human Leukocyte Antigen Matching/Immunosuppression
  Bashoo Naziruddin, PhD

• The Future of Quality Measurement—Metrics that Matter
  Institute of Medicine’s Vital Signs
  TBD
  Clinically-linked Action Measures
  Sheldon Greenfield, MD
  Comprehensive Diabetes and Cardiovascular Quality Measures
  Patrick J. O’Connor, MD, MA, MPH
  Patient-Reported Outcomes
  Andrea L. Cherrington, MD, MPH

• The New Face of Injectable Options
  Inhaled Insulin—Where Are We Going from Here?
  Stefano Del Prato, MD
  Benefits and Limitations of Concentrated Insulin Preparations
  Wendy S. Lane, MD
  Smart Insulins and Nanotechnology for Diabetes Management—Reality or Myth?
  Daniel G. Anderson, PhD
  Swallowing Your Biologic and Not Your Pride
  Chandra P. Sharma, FBAO, FBSE

• Oral Presentations
  • Edwin Bierman Award Lecture
    Clay F. Semenkovich, MD
  • Vivian Fonseca Scholar Award Presentation
    Shashank S. Shah, MD

4:30 p.m.–6:30 p.m.
Symposia
• Targeting PCSK9 for Treatment of Hyperlipidemia—Progress and Controversies
  Genetics, Biology, and Clinical Translation of PCSK9
  Jay D. Horton, MD
  What Do the Clinical Trial Data Show? Update 2016
  Evan Stein, MD, PhD
  Clinical Decision Making—who to Treat and How Do We Afford It?
  Naveed A. Sattar, MD, PhD

• Diabetes and Gluten—Addressing Interrelationships and Treatment Recommendations
  Spectrum of Gluten-related Disorders and Metabolic Implications in Diabetes
  Alessio Fasano, MD
  To Eat Gluten-Free or Not with Type 1 Diabetes
  Andrea E. Scaramuzzo, MD
  Non-celiac Gluten Sensitivity with Prediabetes and Type 2 Diabetes
  Sheila G. Dean, DSc, RDN, LDN, CCN, CDE

• The Role of Continuous Glucose Monitoring in Diabetes Management
  The Value of Continuous Glucose Monitoring in Patients with Type 1 Diabetes Using Multiple Daily Injections—DiaMonD Study
  Study Background
  Janet B. McGill, MD
  Design, Methods, and Baseline Demographics
  Andrew J. Ahmann, MD
  Results and Implications
  Elena Toschi, MD, PhD
  Howard A. Wolpert, MD
  Question and Discussion Period
Is There a Racial Difference in the Mean Continuous Glucose Monitoring Glucose in Relation to the A1c?

Study Background
Rose Gubitosi-Klug, MD, PhD

Design, Methods, and Baseline Demographics
Robin L. Gal, MSPH

Results and Implications
Richard M. Bergenstal, MD
Roy W. Beck, MD, PhD

Question and Discussion Period

• Diabetes and Precision Medicine—What Can We Learn about Diabetes with “Omics”?
  Overview—The Promise of Omics for Clinical Care
  Robert E. Gerstenz, MD
  Epigenetics
  Yongmei Liu, MD, PhD
  Metabolomics
  Svati H. Shah, MD, MHS, FACC
  Microbiomics—Understanding the Role of Nutrition in Vascular and Metabolic Dysfunction
  Nathalie M. Delzenne, PhD

• What Is the Future of Immunotherapy for Type 1 Diabetes?
  Overview—Prevention/Reversal Trials in Type 1 Diabetes
  Jay S. Skler, MD, MACP
  IL-2 Immunotherapy
  Thomas Malek, PhD
  Repurposing Imatinib for Type 1 Diabetes
  Stephen E. Gitelman, MD
  Combination Immunotherapy for Type 1 Diabetes
  Michael Haller, MD, MS-CI

• Insulin Resistance—What We Know and Don’t Know
  The Many Faces of Insulin Resistance
  David E. James, PhD
  Elevation of Retinol Binding Protein 4 in Adipocytes Causes Systemic Insulin Resistance by Inducing Adipose Tissue Inflammation
  Pedro M. Vieira, PhD
  To Store or to Signal? Glycerolipids and Insulin Resistance
  Rosalind Coleman, MD
  Lipid Sensing in the Pancreatic Alpha Cell—Linking Insulin Resistance to Hyperglycemia
  William L. Holland, PhD

• Beyond Taste—Various Functions of Extraoral “Taste” Receptors
  A Role for Beta-Cell Sweet Taste Receptors in Insulin Secretion
  George A. Kyriazis, PhD
  Role of Taste Receptors in Bone and Adipose Biology
  Sebastian D. Parlee, PhD
  The Role of Upper Airway Taste Receptors in the Intersection between Innate Immunity and Diabetes Mellitus
  Robert J. Lee, PhD
  Taste Receptors in Cellular Fuel Sensing
  Melanie H. Cobb, PhD

• Autocrine and Paracrine Signaling between Islet Cell Types
  Neural and Endocrine Cross Talk in the Pancreas
  Alejandro Caicedo, PhD
  Visualizing Endocrine-Cell Interactions Regulating Hormone Secretion
  David W. Piston, PhD
  Extracellular Short RNA-mediated Beta and Target Cell Interactions
  Claudiane Guay, PhD
  Maintaining Endocrine Islet Cell Identity and Function in Diabetes
  Melissa F. Brereton, BSc, PhD

Oral Presentations
• State-of-the-Art Lecture

MONDAY, JUNE 13
8:00 a.m.–10:00 a.m.

Current Issues
• Nature vs. Nurture for Obesity and Metabolic Health
  Metabolically Healthy Obese Individuals Exist, and Are Intrinsically Protected
  Samuel Klein, MD
  Environment Is Key for Healthy Obesity
  Joshua Bell, PhD
  Question and Discussion Period

Symposia
• Joint ADA/ASN Symposium—Innovations in Treating Inflammation for Diabetic Kidney Disease
  Nrf2 Signaling in the Diabetic Kidney—Lessons Learned
  Carlamaria Zoja, PhD
  The Rise of Serum Amyloid A in Diabetic Complications
  Kevin D. O’Brien, MD
  The Impact of JAK Inhibitors in Diabetic Kidney Disease
  Frank C. Brosius III, MD
  The MCP-1 Inhibition Story for Diabetic Kidney Disease
  Hermann Haller, MD

• When Food Access Is the Problem—Improving Diabetes Care and Outcomes in Low-Income Populations in the U.S.
  What Do We Know about Diabetes Care in Low-Income and Food-Insecure Populations?
  Seth A. Berkowitz, MD, MPH
  Feeding America Community-based Diabetes Initiatives—Past, Present, and Future
  Kim Prendergast, RD, MPP
  Advocacy and Health Care Policy Tools to Improve Diabetes Outcomes in Low-Income Populations
  Sarah Downer, JD

• Exercise as the Afterburner for the Post-bariatric Surgery Patient
  Physiological Underpinnings of Choosing Exercise and Food after Bariatric Surgery
  Carel W. le Roux, FRCP, PhD
  Cellular Responses that Require Exercise Post-bariatric Surgery
  Paul M. Coen, PhD
  Metabolic Adaptations that Alter Bioenergetics and Body Composition
  Kevin D. Hall, PhD

Speakers and presentation titles are subject to change.
• Risk-based Contracting—Preparing for the Inevitable
  Policy Rationale/Implications
  TBD
  Academic Medical Center
  Bruce E. Landon, MD, MBA
  Health Care System
  Adam M. Licurse, MD, MHS
  Private Insurer
  Deneen Votja, MD

• Metabolic Reproductive Syndrome (MRS)—A New Look at Polycystic Ovary Syndrome (PCOS)
  Update on the Genetics and Pathophysiology of MRS
  Andrea Dunaif, MD
  Clinical Update and Implications—Renaming PCOS
  Helena J. Teede, MBBS, FRACP, PhD
  Treatment Approaches for MRS—Current and Novel
  David A. Ehrmann, MD
  Fertility Implications for Obesity
  Richard S. Legro, MD

• ADA Pathway To Stop Diabetes Symposium
  The Sense of Smell Impacts Metabolic Health and Obesity
  Celine Emmanuelle Riera, PhD
  The Genetic and Epigenetic Regulatory Signature of Type 2 Diabetes in Human Skeletal Muscle
  Stephen C.J. Parker, PhD
  Shared Genetic Determinants of Glycemic Traits In and Outside of Pregnancy
  Marie-France Hivert, MD, MMSc
  Ablation of the Akt/mTORC1 Repressor REDD1 Prevents Diabetes-induced Visual Dysfunction
  Michael D. Dennis, PhD
  Targeting LMPTP for Obesity-associated Diabetes Therapy
  Stephanie Stanford, PhD
  Autoreactive CD4 T Cells Target Hybrid Insulin Peptides in Type 1 Diabetes
  Thomas Delong, PhD

• Deconstructing Cellular Heterogeneity in Diabetes-relevant Tissues
  Islet Cell Transcriptomes
  Michael L. Stitziel, PhD
  Gene Profiling of Brown and White Preadipocytes
  Yu-Hua Tseng, PhD
  Single Cell Heterogeneity in the Mammalian Liver
  Shalev Itzkovitz, PhD
  Engineering T Cells
  Todd M. Brusko, PhD

• Fibrosis and Insulin Action
  State-of-the-Art Fibrotic Imaging
  Moshe Levi, MD
  Updates on Adipose and Liver Fibrosis
  Karine Clément, MD, PhD
  Extracellular Matrix and Insulin Resistance
  Li Kang, PhD
  High-Fat Diets and Liver Fibrosis
  Donald B. Jump, PhD

• Immune Cells in the Islet—Always the Bad Guys?
  Amyloid-induced Inflammation and Islet Dysfunction
  Bruce Verchere, PhD
  The Role of Macrophages in Beta-Cell Proliferation
  Xiangwei Xiao, MD, PhD
  Macrophage-mediated Beta-Cell Regeneration
  Marcela Brissova, PhD
  The Role of Islet Inflammation in Type 2 Diabetes
  Marc Y. Donath, MD

Oral Presentations
10:15 a.m.–11:45 a.m.
• National Scientific & Health Care Achievement Awards Presentation
• Outstanding Scientific Achievement Award Lecture
  Tamas L. Horvath, DVM, PhD

Noon–2:00 p.m.
• General Poster Session/Moderated Poster Discussions
12:30 p.m.–1:45 p.m.
• Professional Interest Group Discussions

2:15 p.m.–4:15 p.m.
Symposia
• Hypoglycemic Disorders
  When is Hypoglycemia?
  Mark L. Evans, MD, FRCP
  Hypoglycemic Disorders in Children
  Diva D. De León-Crutchlow, MD, MSCE
  Spectrum of Hypoglycemic Disorders in Adults
  Adrian Vella, MD
  Question and Discussion Period
• Behavioral Intervention Trials—Who Doesn't Respond and Why
  How Can We Move Behavioral Intervention Nonresponders to Be Responders?
  Korey K. Hood, PhD
  Does Everyone Respond the Same Way? Experiences from the TODAY Trial
  Elizabeth M. Venditti, PhD
  Case Studies from the Field—Iteratively Adapting Behavioral Interventions to Maximize Patient Response
  Monica E. Peek, MD, MPH
  Theoretical Considerations around Nonresponse to Interventions
  David G. Marrero, PhD

• Designing Transitional-Care Programs and Communication Strategies to Improve Quality and Reduce Admissions
  Thirty-Day Readmissions among Patients with Diabetes—What Do the Data Tell Us?
  Daniel J. Rubin, MD, MSc, FACE
  Overcoming the Barriers and Challenges of Educating Hospitalized Patients with Diabetes
  Amy C. Donihi, PharmD, BCPS
  Transitional Care Program for High-Risk Diabetes Patients—A Feasibility Study
  Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAAN
  The Role of Individualized Diabetes Survival Skills Education in Improving Care Transitions
  Kathleen M. Dungan, MD, MPH

• In Response to the Tsunami—New Models of Care to More Effectively Treat Gestational Diabetes Mellitus and Maternal Obesity
  Is Telemedicine a Viable Strategy to Treat Gestational Diabetes Mellitus?
  David A. Sacks, MD
  Group Prenatal Care for Pregnancies Affected by Gestational Diabetes Mellitus
  Sara E. Mazzoni, MD, MPH
  Advances in Utilizing Glucose Data Remotely—Reimbursable or Time Sink?
  Mary Voelml, MS, FNP, CDE
  eHealth (Mobile Apps and Websites) to Improve Pregnancy Outcomes and Postpartum Weight Loss
  Jacinda M. Nicklas, MD, MPH

• Joint ADA/JDRF Symposium—Optimizing Use of Technology and Therapeutics in Pediatric Diabetes
  Status of Insulin Pump and Continuous Glucose Monitoring Use in Pediatric Diabetes
  Jenise C. Wong, MD, PhD
  Automated Insulin Delivery and Biannual Artificial Pancreas in Pediatrics—Coming Soon!
  Trang T. Ly, PhD, MBBS, FRACP
  Alternate Delivery Methods of Glucagon and Insulin in Pediatrics
  Jennifer L. Sherr, MD, PhD
  Information Overload—Or Is It?
  Saleh Adi, MD

• Results of the Liraglutide Effect and Action in Diabetes—Evaluation of Cardiovascular Outcome Results (LEADER) Trial
  Session information not available at time of printing.

• Genetic Analysis of Gut Flora in Diabetes and Metabolic Disease
  The Human Microbiome
  George Weinstock, PhD
  The Microbiome and Metabolic Disease
  Remy Burcelin, PhD
  Gut Microbiota and Type 1 Diabetes
  Aleksandar D. Kostic, PhD
  The Environmental Determinants of Diabetes in the Young (TEDDY) Project
  Joseph Petrosino, PhD

• Human Brown Fat
  Overview and Potential for Therapeutic Targeting of Brown Fat in Human Obesity
  Jan Nedergaard, PhD
  Genetic and Functional Characterization of Human Brown Adipocytes
  Shingo Kajimura, PhD
  Browning of Subcutaneous White Adipose Tissue in Humans
  Labros S. Sidossis, PhD
  Transcriptional Mechanisms Mediating Browning of Human Adipocytes
  Susanne Mandrup, PhD

Oral Presentations
### 4:30 p.m.–6:30 p.m.

**Symposia**

- **Therapy of Diabetic Neuropathy—We Can Do Better**  
  Amputations Are Increasing and the Foot Clinics Are Bursting—What Can We Do? Amputation Risk and Neuropathy—The State of the Problem  
  Katherine Gallagher, MD  
  Amputations Are Increasing and the Foot Clinics Are Bursting—What Can We Do? Is Early Diabetic Neuropathy Reversible (or Preventable)?  
  Lucy M. Hinder, PhD  
  Amputations Are Increasing and the Foot Clinics Are Bursting—What Can We Do? Is Late Diabetic Neuropathy Reversible (or Preventable)?  
  Rayaz A. Malik, BSc, MSc, MB, ChB, FRCP, PhD  
  Beyond the Guidelines—How to Manage Painful Neuropathy in Clinical Practice Personalized Pain Therapy—Lessons from Pain Phenotyping and Neuroimaging  
  Solomon Tesfaye, MB, ChB, MD, FRCP  
  Beyond the Guidelines—The Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy—Current and Future Approaches  
  Roy L. Freeman, MD  
  Question and Discussion Period

- **More than a Gut Instinct—Potential of the Microbiome from Pregnancy through the Life Cycle**  
  Overview of the Human Microbiome and Mechanisms for Mediating Metabolic Risk  
  Michael Rosenbaum, MD  
  Bioactive Components of Breast Milk and Evolution of the Infant Microbiome  
  Lars Bode, PhD  
  The Early Microbiome and Risk for Development of Type 1 Diabetes  
  Mark A. Atkinson, PhD  
  The Microbiome Phenotype in Obesity and Type 2 Diabetes Mellitus and Potential Therapeutics  
  Annick V. Hartstra, MD

- **Insulin Resistance, Statin Treatment, and Exercise—Incompatible Partners?**  
  How Are Insulin Resistance and Skeletal Muscle Mitochondrial Function Related?  
  Flemming Dela, MD, DMSc  
  The Impact of Statin Myalgia on Muscle Performance and Cellular Regulation of Fuel Use  
  Paul Greenhaff, PhD  
  Interaction between Statins, Exercise, and Muscle Symptoms  
  Beth A. Taylor, PhD

- **NIDDK/NCI Symposium—Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer**  
  Overview of Diabetes and Pancreatic Ductal Adenocarcinoma (PDAC)  
  Murray Korc, MD  
  Genomic Correlations among Diabetes, Chronic Pancreatitis, and PDAC  
  Gloria M. Petersen, PhD  
  Role of Obesity- and Pancreatitis-associated Inflammation in the Development of PDAC  
  Guido Eibl, MD  
  Antidiabetic Medications and Pancreatic Cancer  
  Donghui Li, PhD  
  Pancreatogenic (Type 3c) Diabetes—Prevalence, Differentiation from Type 2 Diabetes Mellitus, and Importance of Recognition  
  Michael R. Rickels, MD, MS  
  Mechanisms of PDAC-induced Diabetes  
  Suresh T. Chari, MD  
  Panel Discussion/Question and Discussion Period  
  Murray Korc, MD  
  Gloria M. Petersen, PhD  
  Guido Eibl, MD  
  Donghui Li, PhD  
  Michael R. Rickels, MD, MS  
  Suresh T. Chari, MD

---

**Join Now**

**AND START SAVING**

at ADA's 76th Scientific Sessions

**ADA Members SAVE $320 on registration, plus receive these professional benefits:**

- Free webcasts of the Sessions  
- Free ADA journal  
- Access to ADA’s Career Center  
- Networking with your peers

[Visit the membership booth while you’re at Scientific Sessions to learn more!](professional.diabetes.org/join)
• What Can Lipodystrophies Teach Us about Diabetes?
PPARγ and Lipodystrophies
Todd Leff, PhD
Lipodystrophy and Lipid Metabolism in Human Studies
Rebecca J. Brown, MD, MHSc
Favorable Adiposity
Timothy M. Frayling, PhD
Human Causes and Consequences of Lipodystrophies
Antonio Vidal-Puig, MD, PhD, FRCP, FMedSci, EMBA

• Beta-Cell Stimulus-Secretion Coupling—What’s New?
Metabolic Signaling in Insulin Secretion and Diabetes
Robert A. Screaton, PhD
Second Messengers in Potentiating Insulin Secretion
Susumu Seino, MD, DMSci
Exciting Granule Fusion in Beta Cells through the Cytoskeleton
Debbie C. Thurmond, PhD
Modulating Beta Cell Function by Noncoding RNAs
Lena Eliasson, MSc, PhD

Moving On Up—Transition to Adulthood and Adult Care for Young Adults with Type 1 Diabetes
Cognitive Development and Communication with Providers among Young Adults with Type 1 Diabetes
Maureen Monaghan, PhD
Risk Behaviors Related to Type 1 Diabetes Management in Adolescents and Young Adults
Diana Naranjo, PhD
Developing and Implementing a Model of Health Care Delivery for Transition Preparation in Type 1 Diabetes
Sarah K. Lyons, MD
Design and Validation of a Transition/Preparation Readiness Skills Measure
Joyce P. Yi-Frazier, PhD

• Update from the EMPA-REG Outcome Trial
Introduction, Context, and Cardiovascular Outcomes
Bernard Zinman, CM, MD, FRCP, FACP
Clinical Implications—A Cardiologist’s Perspective
Darren K. McGuire, MD, MHSc
Update on Microvascular Outcomes
Christoph Wanner, MD
Further Insights into the Findings—Mediation Analysis (Methods)
John M. Lachin, ScD
Further Insights into the Findings—Mediation Analysis (Results)
Silvio E. Inzucchi, MD
Question and Discussion Period

• Fifty Winks of Diabetes
The Molecular Clock as a Metabolic Rheostat
Joseph T. Bass, MD, PhD
Circadian Disruption, Sleep Apnea, and Metabolism—Insights from Animal Models
Deanna M. Arble, PhD
Circadian Timing of Metabolism in Mouse Models and Humans
Charna Dibner, PhD
Epigenetic Control and the Circadian Clock—Linking Metabolism to Neuronal Responses
Paolo Sassone-Corsi, PhD

• Metabolic Endotoxemia—Is It Real? Who Are the Players?
Does Metabolic Endotoxemia Exist in Obesity and Type 2 Diabetes?
Matthew W. Hulver, PhD
The Origin of Metabolic Endotoxemia—Gut Microbes, Gut Barrier, and Beyond
Patrice D. Cani, PhD
Metabolic Effects of Endotoxin Signaling
Nicolas Musi, MD
Panel Discussion/Question and Discussion Period
Matthew W. Hulver, PhD
Patrice D. Cani, PhD
Nicolas Musi, MD

• Impact of Intrauterine Environment on Beta-Cell Dysfunction and Diabetes
The Role of Maternal Diet and mTOR Signaling in Beta-Cell Dysfunction in Offspring
Emilyn Alejandro, PhD
Developmental Programming of Type 2 Diabetes
Susan E. Ozanne, PhD
Fetal Growth Restriction and Adult Diabetes—Molecular Mechanisms
Rebecca A. Simmons, MD
IUGR Consequences and Treatments in Humans
Laura Brown, MD

Speakers and presentation titles are subject to change.
“The Pathway Award is giving me a voice in a new field of study and allowing me to introduce a novel angle to the classical approaches undertaken to study diabetes.”

Celine Emmanuelle Riera, PhD
Pathway Initiator Award Recipient 2015

We’re seeking brilliant minds at the peak of their creativity, regardless of their current field of study. Now in its fourth year, Pathway to Stop Diabetes® provides five- to seven-year grants of $1.625 million, along with the freedom, autonomy, professional mentoring and collaborative opportunities to drive new breakthroughs in diabetes research. Learn more about Pathway today. And help put an end to diabetes.